I am reversing my rating on Akero Therapeutics stock from Buy to Sell due to valuation concerns and a long-ish wait for ...

Akero Therapeutics (AKRO) announced publication of 96-week final results from the Phase 2b HARMONY trial in The Lancet in adults with ...

Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high ...

A high-level overview of Akero Therapeutics, Inc. (AKRO) stock. View (AKRO) real-time stock price, chart, news, analysis, analyst reviews and more.

Akero Therapeutics, Inc. is set to hold an investor webcast on January 27, 2025, at 8:00 a.m. ET to present preliminary topline results from its SYMMETRY study, which evaluates the efficacy of ...

In a recent SEC filing, Rolph Timothy, Chief Scientific Officer of Akero Therapeutics, Inc. (NASDAQ:AKRO), disclosed the sale of company shares valued at approximately $1.74 million. The ...

Akero Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic ...

SOUTH SAN FRANCISCO, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious ...

What happenedShares of Akero Therapeutics (NASDAQ: AKRO) were crashing 66.5% lower as of 11:09 a.m. ET on Tuesday. The steep decline came after the company announced interim results from a phase ...

In addition, Akero Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 1,650,000 shares of its common stock at the public offering price, less underwriting ...